Skip to content
Review Open access

Integrating genetics and phenotyping in clinical management of dilated and non-dilated left ventricular cardiomyopathy.

Aug 2026 · European Journal of Heart Failure · 0 citations
Medicine

TL;DR

This review paper aims to provide a structured and evidence-informed framework to guide personalized management of DCM and NDLVC, starting from the phenotype towards precision medicine.

Abstract

Over the past decades, the approach to cardiomyopathies has deeply evolved. It has progressively transitioned from one predominantly based on clinical evaluation and conventional imaging towards an integrated and multidimensional approach that incorporates advanced imaging techniques, tissue characterization, and comprehensive genetic testing. In this perspective, the current classification of cardiomyopathies, from the European Society of Cardiology, has introduced the new entity of non-dilated left ventricular cardiomyopathy (NDLVC) that encompasses a spectrum of diseases from hypokinetic non-dilated forms [formerly called dilated cardiomyopathies (DCMs)] to non-hypokinetic non-dilated forms, characterized by left ventricular scar (previously called arrhythmogenic cardiomyopathies). However, the pivotal principle of the new classification is that the phenotype should be considered the starting point of a dynamic diagnostic pathway rather than its ultimate definition. Contemporary evaluation of patients with DCM and NDLVC requires a longitudinal and integrative perspective in which clinical features, imaging markers, and molecular data converge to refine disease characterization. Stated that, several aspects warrant further refinement. Arrhythmic risk stratification of DCM and NDLVC remains incompletely delineated, reflecting the complex and heterogeneous nature of the underlying arrhythmogenic substrate and its variable expression across different stages of the diseases. In addition, a proportion of patients remain genetically elusive despite extensive testing, underscoring the need for deeper molecular insights. At the same time, the expanding recognition of genotype-positive/phenotype-negative individuals introduces clinical scenarios that are not yet fully delineated, particularly with regard to surveillance strategies and preventive decision-making. This review paper aims to provide a structured and evidence-informed framework to guide personalized management of DCM and NDLVC, starting from the phenotype towards precision medicine.

Read PDF

Similar papers

Review Open access Sep 2026

Non-Dilated Left Ventricular Cardiomyopathy: Exploring the Spectrum from Phenotype to Disease Entity

Non-dilated left ventricular cardiomyopathy has recently emerged as a distinct morpho-functional phenotype defined by non-ischemic left ventricular scarring or fatty replacement or by isolated global left ventricular hypokinesia without scarring in the absence of ventricular dilatation. Whether it represents a distinct...

F. Mangini, Massimo Grimaldi, A. di Monaco et al. · 0 citations
Review Open access Sep 2026

Complication management in hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, yet remains substantially underdiagnosed in clinical practice. Although current guidelines define HCM primarily based on left ventricular wall thickness, this approach alone does not capture the full spectrum of disease expression. Compreh...

Viktoria Höller, P. Zwetsloot, V. Santner et al. · 0 citations
Open access Aug 2026

Diffuse generalized phenotype of hypertrophic cardiomyopathy: genetic spectrum and surgical correction

Introduction. Hypertrophic cardiomyopathy (HCM) is characterized by clinical and genetic heterogeneity. Age of manifestation, clinical and anatomical phenotypes of HCM vary significantly. This study discusses genetic causes and reconstructive surgery results for patients with particular intracardiac phenotype - diffuse...

S. Dzemeshkevich, M. Balashova, M. Polyak et al. · 0 citations
Review Open access Sep 2026

Multimodality Imaging in Hypertrophic Cardiomyopathy: From Phenotyping to Precision Clinical Management

Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous myocardial disease characterized by unexplained left ventricular hypertrophy and a broad spectrum of clinical manifestations, ranging from an asymptomatic phenotype to heart failure, atrial and ventricular arrhythmias, sudden cardiac de...

N. Mileva, P. Panayotov · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.